Head-To-Head Survey: Intensity Therapeutics (INTS) and Its Rivals

Intensity Therapeutics (NASDAQ:INTS – Get Free Report) is one of 610 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its peers? We will compare Intensity Therapeutics to related companies based on the strength of its analyst recommendations, profitability, risk, dividends, valuation, earnings and institutional ownership.

Earnings and Valuation

This table compares Intensity Therapeutics and its peers gross revenue, earnings per share and valuation.

Get Intensity Therapeutics alerts:

Intensity Therapeutics’ peers have higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 7.1% of Intensity Therapeutics shares are held by company insiders. Comparatively, 12.5% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Intensity Therapeutics and its peers, as reported by MarketBeat.com.

Intensity Therapeutics currently has a consensus price target of $37.50, suggesting a potential upside of 709.94%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 71.04%. Given Intensity Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Intensity Therapeutics is more favorable than its peers.

Profitability

This table compares Intensity Therapeutics and its peers’ net margins, return on equity and return on assets.

Risk and Volatility

Intensity Therapeutics has a beta of 2.94, indicating that its share price is 194% more volatile than the S&P 500. Comparatively, Intensity Therapeutics’ peers have a beta of 1.07, indicating that their average share price is 7% more volatile than the S&P 500.

Summary

Intensity Therapeutics beats its peers on 7 of the 13 factors compared.

About Intensity Therapeutics

(Get Free Report)

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.